Skip to main content
Erschienen in: Pathology & Oncology Research 4/2018

08.09.2017 | Original Article

RETRACTED ARTICLE: MiR-184 Retarded the Proliferation, Invasiveness and Migration of Glioblastoma Cells by Repressing Stanniocalcin-2

Erschienen in: Pathology & Oncology Research | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

To investigate the repression of miR-184 on Stanniocalcin-2 (STC2) and how this axis affects the propagation, invasiveness and migration ability of glioblastoma cells. RT-PCR was employed to determine the miR-184 and STC2 mRNA expression both in tissues and cells. Western blot was employed to determine the protein expression levels. The cells were transfected via lipofection. MTT, colony formation, invasion and scratch healing assays were conducted to study the propagation, invasiveness and migratory ability of glioblastoma cells, respectively. The dual luciferase reporter gene assay was conducted to determine whether miR-184 could directly bind to STC2 mRNA 3’UTR. MiR-184 was under-expressed whereas STC2 was over-expressed in glioblastoma tissues and cell line. The up-regulation of miR-184 significantly suppressed the propagation, migratory ability and invasion of glioblastoma cells, whereas the over-expression of STC2 restored this effect. MiR-184 was confirmed to directly target STC2. MiR-184 could retard the propagation, invasiveness and migratory ability of glioblastoma cells by suppressing STC2.
Literatur
1.
Zurück zum Zitat Kouhkan F, Mobarra N, Soufi-Zomorrod M et al (2016) MicroRNA-129-1 acts as tumour suppressor and induces cell cycle arrest of GBM cancer cells through targeting IGF2BP3 and MAPK1. J Med Genet 53:24–33CrossRefPubMed Kouhkan F, Mobarra N, Soufi-Zomorrod M et al (2016) MicroRNA-129-1 acts as tumour suppressor and induces cell cycle arrest of GBM cancer cells through targeting IGF2BP3 and MAPK1. J Med Genet 53:24–33CrossRefPubMed
2.
Zurück zum Zitat Zhen L, Li J, Zhang M, et al. MiR-10b decreases sensitivity of glioblastoma cells to radiation by targeting AKT. J Biol Res (Thessalon). 2016;23:14 Zhen L, Li J, Zhang M, et al. MiR-10b decreases sensitivity of glioblastoma cells to radiation by targeting AKT. J Biol Res (Thessalon). 2016;23:14
3.
Zurück zum Zitat Zhang W, Zhang J, Yan W et al (2013) Whole-genome microRNA expression profiling identifies a 5-microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme. Cancer 119:814–824CrossRefPubMed Zhang W, Zhang J, Yan W et al (2013) Whole-genome microRNA expression profiling identifies a 5-microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme. Cancer 119:814–824CrossRefPubMed
4.
Zurück zum Zitat Sizoo EM, Braam L, Postma TJ et al (2010) Symptoms and problems in the end-of-life phase of high-grade glioma patients. Neuro-Oncology 12:1162–1166CrossRefPubMedPubMedCentral Sizoo EM, Braam L, Postma TJ et al (2010) Symptoms and problems in the end-of-life phase of high-grade glioma patients. Neuro-Oncology 12:1162–1166CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Agnihotri S, Burrell KE, Wolf A et al (2013) Glioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategies. Arch Immunol Ther Exp 61:25–41CrossRef Agnihotri S, Burrell KE, Wolf A et al (2013) Glioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategies. Arch Immunol Ther Exp 61:25–41CrossRef
6.
Zurück zum Zitat Cheng Z, Wang HZ, Li X et al (2015) MicroRNA-184 inhibits cell proliferation and invasion, and specifically targets TNFAIP2 in Glioma. J Exp Clin Cancer Res 34:27CrossRefPubMedPubMedCentral Cheng Z, Wang HZ, Li X et al (2015) MicroRNA-184 inhibits cell proliferation and invasion, and specifically targets TNFAIP2 in Glioma. J Exp Clin Cancer Res 34:27CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Iorio MV, Croce CM (2012) MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 4:143–159CrossRefPubMedPubMedCentral Iorio MV, Croce CM (2012) MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 4:143–159CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Sethi S, Ali S, Sethi S et al (2014) MicroRNAs in personalized cancer therapy. Clin Genet 86:68–73CrossRefPubMed Sethi S, Ali S, Sethi S et al (2014) MicroRNAs in personalized cancer therapy. Clin Genet 86:68–73CrossRefPubMed
9.
Zurück zum Zitat Yang BF, Lu YJ, Wang ZG (2009) MicroRNAs and apoptosis: implications in the molecular therapy of human disease. Clin Exp Pharmacol Physiol 36:951–960CrossRefPubMed Yang BF, Lu YJ, Wang ZG (2009) MicroRNAs and apoptosis: implications in the molecular therapy of human disease. Clin Exp Pharmacol Physiol 36:951–960CrossRefPubMed
10.
Zurück zum Zitat Zhou R, Zhou X, Yin Z et al (2015) Tumor invasion and metastasis regulated by microRNA-184 and microRNA-574-5p in small-cell lung cancer. Oncotarget 6:44609–44622CrossRefPubMedPubMedCentral Zhou R, Zhou X, Yin Z et al (2015) Tumor invasion and metastasis regulated by microRNA-184 and microRNA-574-5p in small-cell lung cancer. Oncotarget 6:44609–44622CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Qin CZ, Lou XY, Lv QL et al (2015) MicroRNA-184 acts as a potential diagnostic and prognostic marker in epithelial ovarian cancer and regulates cell proliferation, apoptosis and inflammation. Pharmazie 70:668–673PubMed Qin CZ, Lou XY, Lv QL et al (2015) MicroRNA-184 acts as a potential diagnostic and prognostic marker in epithelial ovarian cancer and regulates cell proliferation, apoptosis and inflammation. Pharmazie 70:668–673PubMed
13.
Zurück zum Zitat Feng R, Dong L (2015) Inhibitory effect of miR-184 on the potential of proliferation and invasion in human glioma and breast cancer cells in vitro. Int J Clin Exp Pathol 8:9376–9382PubMedPubMedCentral Feng R, Dong L (2015) Inhibitory effect of miR-184 on the potential of proliferation and invasion in human glioma and breast cancer cells in vitro. Int J Clin Exp Pathol 8:9376–9382PubMedPubMedCentral
14.
Zurück zum Zitat Malzkorn B, Wolter M, Liesenberg F et al (2010) Identification and functional characterization of microRNAs involved in the malignant progression of gliomas. Brain Pathol 20:539–550CrossRefPubMed Malzkorn B, Wolter M, Liesenberg F et al (2010) Identification and functional characterization of microRNAs involved in the malignant progression of gliomas. Brain Pathol 20:539–550CrossRefPubMed
15.
Zurück zum Zitat Chang AC, Janosi J, Hulsbeek M et al (1995) A novel human cDNA highly homologous to the fish hormone stanniocalcin. Mol Cell Endocrinol 112:241–247CrossRefPubMed Chang AC, Janosi J, Hulsbeek M et al (1995) A novel human cDNA highly homologous to the fish hormone stanniocalcin. Mol Cell Endocrinol 112:241–247CrossRefPubMed
16.
Zurück zum Zitat Chang AC, Jeffrey KJ, Tokutake Y et al (1998) Human stanniocalcin (STC): genomic structure, chromosomal localization, and the presence of CAG trinucleotide repeats. Genomics 47:393–398CrossRefPubMed Chang AC, Jeffrey KJ, Tokutake Y et al (1998) Human stanniocalcin (STC): genomic structure, chromosomal localization, and the presence of CAG trinucleotide repeats. Genomics 47:393–398CrossRefPubMed
17.
Zurück zum Zitat Wagner GF, Dimattia GE (2006) The stanniocalcin family of proteins. J Exp Zool A Comp Exp Biol 305:769–780CrossRefPubMed Wagner GF, Dimattia GE (2006) The stanniocalcin family of proteins. J Exp Zool A Comp Exp Biol 305:769–780CrossRefPubMed
18.
Zurück zum Zitat Ito D, Walker JR, Thompson CS et al (2004) Characterization of stanniocalcin 2, a novel target of the mammalian unfolded protein response with cytoprotective properties. Mol Cell Biol 24:9456–9469CrossRefPubMedPubMedCentral Ito D, Walker JR, Thompson CS et al (2004) Characterization of stanniocalcin 2, a novel target of the mammalian unfolded protein response with cytoprotective properties. Mol Cell Biol 24:9456–9469CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Gagliardi AD, Kuo EY, Raulic S et al (2005) Human stanniocalcin-2 exhibits potent growth-suppressive properties in transgenic mice independently of growth hormone and IGFs. Am J Physiol Endocrinol Metab 288:E92–105CrossRefPubMed Gagliardi AD, Kuo EY, Raulic S et al (2005) Human stanniocalcin-2 exhibits potent growth-suppressive properties in transgenic mice independently of growth hormone and IGFs. Am J Physiol Endocrinol Metab 288:E92–105CrossRefPubMed
20.
Zurück zum Zitat Wang Y, Gao Y, Cheng H et al (2015) Stanniocalcin 2 promotes cell proliferation and cisplatin resistance in cervical cancer. Biochem Biophys Res Commun 466:362–368CrossRefPubMed Wang Y, Gao Y, Cheng H et al (2015) Stanniocalcin 2 promotes cell proliferation and cisplatin resistance in cervical cancer. Biochem Biophys Res Commun 466:362–368CrossRefPubMed
21.
Zurück zum Zitat Na SS, Aldonza MB, Sung HJ et al (1854) Stanniocalcin-2 (STC2): a potential lung cancer biomarker promotes lung cancer metastasis and progression. Biochim Biophys Acta 2015:668–676 Na SS, Aldonza MB, Sung HJ et al (1854) Stanniocalcin-2 (STC2): a potential lung cancer biomarker promotes lung cancer metastasis and progression. Biochim Biophys Acta 2015:668–676
22.
Zurück zum Zitat Hou J, Wang Z, Xu H et al (2015) Stanniocalicin 2 suppresses breast cancer cell migration and invasion via the PKC/claudin-1-mediated signaling. PLoS One 10:e0122179CrossRefPubMedPubMedCentral Hou J, Wang Z, Xu H et al (2015) Stanniocalicin 2 suppresses breast cancer cell migration and invasion via the PKC/claudin-1-mediated signaling. PLoS One 10:e0122179CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Guo GX, Li QY, Ma WL et al (2015) MicroRNA-485-5p suppresses cell proliferation and invasion in hepatocellular carcinoma by targeting stanniocalcin 2. Int J Clin Exp Pathol 8:12292–12299PubMedPubMedCentral Guo GX, Li QY, Ma WL et al (2015) MicroRNA-485-5p suppresses cell proliferation and invasion in hepatocellular carcinoma by targeting stanniocalcin 2. Int J Clin Exp Pathol 8:12292–12299PubMedPubMedCentral
24.
Zurück zum Zitat Lin S, Guo Q, Wen J et al (2014) Survival analyses correlate stanniocalcin 2 overexpression to poor prognosis of nasopharyngeal carcinomas. J Exp Clin Cancer Res 33:26CrossRefPubMedPubMedCentral Lin S, Guo Q, Wen J et al (2014) Survival analyses correlate stanniocalcin 2 overexpression to poor prognosis of nasopharyngeal carcinomas. J Exp Clin Cancer Res 33:26CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Su J, Guo B, Zhang T et al (2015) Stanniocalcin-1, a new biomarker of glioma progression, is associated with prognosis of patients. Tumour Biol 36:6333–6339CrossRefPubMed Su J, Guo B, Zhang T et al (2015) Stanniocalcin-1, a new biomarker of glioma progression, is associated with prognosis of patients. Tumour Biol 36:6333–6339CrossRefPubMed
26.
Zurück zum Zitat Yamamoto K, Tajima Y, Hasegawa A et al (2016) Contrasting effects of stanniocalcin-related polypeptides on macrophage foam cell formation and vascular smooth muscle cell migration. Peptides 82:120–127CrossRefPubMed Yamamoto K, Tajima Y, Hasegawa A et al (2016) Contrasting effects of stanniocalcin-related polypeptides on macrophage foam cell formation and vascular smooth muscle cell migration. Peptides 82:120–127CrossRefPubMed
27.
Zurück zum Zitat Jepsen MR, Kloverpris S, Botkjaer JA et al (2016) The proteolytic activity of pregnancy-associated plasma protein-a is potentially regulated by stanniocalcin-1 and -2 during human ovarian follicle development. Hum Reprod 31:866–874CrossRefPubMed Jepsen MR, Kloverpris S, Botkjaer JA et al (2016) The proteolytic activity of pregnancy-associated plasma protein-a is potentially regulated by stanniocalcin-1 and -2 during human ovarian follicle development. Hum Reprod 31:866–874CrossRefPubMed
28.
Zurück zum Zitat Zhou H, Li YY, Zhang WQ et al (2014) Expression of stanniocalcin-1 and stanniocalcin-2 in laryngeal squamous cell carcinoma and correlations with clinical and pathological parameters. PLoS One 9:e95466CrossRefPubMedPubMedCentral Zhou H, Li YY, Zhang WQ et al (2014) Expression of stanniocalcin-1 and stanniocalcin-2 in laryngeal squamous cell carcinoma and correlations with clinical and pathological parameters. PLoS One 9:e95466CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Law AY, Wong CK (2013) Stanniocalcin-1 and -2 promote angiogenic sprouting in HUVECs via VEGF/VEGFR2 and angiopoietin signaling pathways. Mol Cell Endocrinol 374:73–81CrossRefPubMed Law AY, Wong CK (2013) Stanniocalcin-1 and -2 promote angiogenic sprouting in HUVECs via VEGF/VEGFR2 and angiopoietin signaling pathways. Mol Cell Endocrinol 374:73–81CrossRefPubMed
30.
Zurück zum Zitat Yao YL, Ma J, Wang P et al (2015) miR-101 acts as a tumor suppressor by targeting Kruppel-like factor 6 in glioblastoma stem cells. CNS Neurosci Ther 21:40–51CrossRefPubMed Yao YL, Ma J, Wang P et al (2015) miR-101 acts as a tumor suppressor by targeting Kruppel-like factor 6 in glioblastoma stem cells. CNS Neurosci Ther 21:40–51CrossRefPubMed
31.
Zurück zum Zitat Yuan Q, Gao W, Liu B et al (2014) Upregulation of miR-184 enhances the malignant biological behavior of human glioma cell line A172 by targeting FIH-1. Cell Physiol Biochem 34:1125–1136CrossRefPubMed Yuan Q, Gao W, Liu B et al (2014) Upregulation of miR-184 enhances the malignant biological behavior of human glioma cell line A172 by targeting FIH-1. Cell Physiol Biochem 34:1125–1136CrossRefPubMed
32.
Zurück zum Zitat Gao B, Gao K, Li L et al (2014) miR-184 functions as an oncogenic regulator in hepatocellular carcinoma (HCC). Biomed Pharmacother 68:143–148CrossRefPubMed Gao B, Gao K, Li L et al (2014) miR-184 functions as an oncogenic regulator in hepatocellular carcinoma (HCC). Biomed Pharmacother 68:143–148CrossRefPubMed
33.
Zurück zum Zitat Zhen Y, Liu Z, Yang H et al (2013) Tumor suppressor PDCD4 modulates miR-184-mediated direct suppression of C-MYC and BCL2 blocking cell growth and survival in nasopharyngeal carcinoma. Cell Death Dis 4:e872CrossRefPubMedPubMedCentral Zhen Y, Liu Z, Yang H et al (2013) Tumor suppressor PDCD4 modulates miR-184-mediated direct suppression of C-MYC and BCL2 blocking cell growth and survival in nasopharyngeal carcinoma. Cell Death Dis 4:e872CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Wagner GF, Jaworski E (1994) Calcium regulates stanniocalcin mRNA levels in primary cultured rainbow trout corpuscles of stannius. Mol Cell Endocrinol 99:315–322CrossRefPubMed Wagner GF, Jaworski E (1994) Calcium regulates stanniocalcin mRNA levels in primary cultured rainbow trout corpuscles of stannius. Mol Cell Endocrinol 99:315–322CrossRefPubMed
35.
Zurück zum Zitat Shen XJ, Gu K, Shi JP et al (2014) Increased expression of stanniocalcin 2 is associated with tumor progression after radiotherapy in patients with cervical carcinoma. Int J Clin Exp Pathol 7:8770–8776PubMedPubMedCentral Shen XJ, Gu K, Shi JP et al (2014) Increased expression of stanniocalcin 2 is associated with tumor progression after radiotherapy in patients with cervical carcinoma. Int J Clin Exp Pathol 7:8770–8776PubMedPubMedCentral
36.
Zurück zum Zitat Arigami T, Uenosono Y, Ishigami S et al (2013) Clinical significance of stanniocalcin 2 expression as a predictor of tumor progression in gastric cancer. Oncol Rep 30:2838–2844CrossRefPubMed Arigami T, Uenosono Y, Ishigami S et al (2013) Clinical significance of stanniocalcin 2 expression as a predictor of tumor progression in gastric cancer. Oncol Rep 30:2838–2844CrossRefPubMed
37.
Zurück zum Zitat Wang H, Wu K, Sun Y et al (2012) STC2 is upregulated in hepatocellular carcinoma and promotes cell proliferation and migration in vitro. BMB Rep 45:629–634CrossRefPubMedPubMedCentral Wang H, Wu K, Sun Y et al (2012) STC2 is upregulated in hepatocellular carcinoma and promotes cell proliferation and migration in vitro. BMB Rep 45:629–634CrossRefPubMedPubMedCentral
Metadaten
Titel
RETRACTED ARTICLE: MiR-184 Retarded the Proliferation, Invasiveness and Migration of Glioblastoma Cells by Repressing Stanniocalcin-2
Publikationsdatum
08.09.2017
Erschienen in
Pathology & Oncology Research / Ausgabe 4/2018
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-017-0298-z

Weitere Artikel der Ausgabe 4/2018

Pathology & Oncology Research 4/2018 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.